Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.69 |
| ▸ | GAA | P10253 | 7/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | HTT | P42858 | 4/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1684397 | 0.99 | MAPT (0.71) | MAPTGAAALDH1A1KMT2AHTT | |
| SCHEMBL1674889 | 0.89 | MAPT (0.74) | MAPTGAAALDH1A1KMT2AHTT | |
| Bromide SCHEMBL25331121 | 0.88 | MAPT (0.75) | MAPTGAAALDH1A1KMT2AHTT | |
| SCHEMBL1674900 | 0.88 | MAPT (0.69) | MAPTGAAALDH1A1KMT2AHTT | |
| SCHEMBL1684748 | 0.88 | MAPT (0.72) | MAPTGAAALDH1A1KMT2AHTT | |
| Bromide SCHEMBL18040691 | 0.87 | MAPT (0.71) | MAPTGAAALDH1A1KMT2AHTT | |
| SCHEMBL1684568 | 0.83 | MAPT (0.98) | MAPTGAAALDH1A1KMT2AHTT | |
| Bromide SCHEMBL22817531 | 0.82 | GAA (1.00) | MAPTGAAALDH1A1KMT2AHTT | |
| SCHEMBL1684913 | 0.82 | MAPT (0.72) | MAPTGAAALDH1A1KMT2AHTT | |
| SCHEMBL1684486 | 0.82 | MAPT (0.73) | MAPTGAAALDH1A1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2306836-B1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS INC (US) | 2016-09-07 | — | — | EP | claimed |
| US-8680113-B2 | BMI-1 protein expression modulators | PTC THERAPEUTICS, INC. (US) | 2014-03-25 | — | — | US | claimed |
| US-8614063-B2 | Methods for screening for compounds for treating cancer | PTC THERAPEUTICS, INC. (US) | 2013-12-24 | — | — | US | claimed |
| US-20110190239-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | claimed |
| EP-2306836-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC Therapeutics, Inc. (US) | 2011-04-13 | — | — | EP | claimed |
| WO-2010002985-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS, INC. (US) | 2010-01-07 | — | — | WO | claimed |
| EP-3111956-B1 | BMI 1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-3111956-B1 | BMI 1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-3111956-A1 | BMI 1 PROTEIN EXPRESSION MODULATORS | PTC Therapeutics, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2306836-B1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20160067241-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2014179528-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2014-11-06 | — | — | WO | disclosed |
| US-8614063-B2 | Methods for screening for compounds for treating cancer | PTC THERAPEUTICS, INC. (US) | 2013-12-24 | — | — | US | disclosed |
| EP-2307573-B1 | METHODS FOR SCREENING FOR COMPOUNDS FOR TREATING CANCER | PTC THERAPEUTICS INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20110165581-A1 | METHODS FOR SCREENING FOR COMPOUNDS FOR TREATING CANCER | PTC THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165581-A1 | METHODS FOR SCREENING FOR COMPOUNDS FOR TREATING CANCER | PTC THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110165581-A1 | METHODS FOR SCREENING FOR COMPOUNDS FOR TREATING CANCER | PTC THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2307573-A1 | METHODS FOR SCREENING FOR COMPOUNDS FOR TREATING CANCER | PTC Therapeutics, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010002987-A1 | METHODS FOR SCREENING FOR COMPOUNDS FOR TREATING CANCER | PTC THERAPEUTICS, INC (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010002987-A1 | METHODS FOR SCREENING FOR COMPOUNDS FOR TREATING CANCER | PTC THERAPEUTICS, INC (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190239-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | BMI1, CREBBP, BAZ2A | MAPT 4026/4885GAA 3522/4885ALDH1A1 2357/4885 |
| US-20160067241-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | MYC, NME2, TP53 | MAPT 3712/4885GAA 351/4885ALDH1A1 1520/4885 |
| US-20110165581-A1 | METHODS FOR SCREENING FOR COMPOUNDS FOR TREATING CANCER | BMI1, NSUN2, BRDT | MAPT 4678/4885GAA 2413/4885ALDH1A1 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.